Drugs /

vandetanib

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
vandetanib
Trade Name(s):
Zactima and Caprelsa
NCI Definition [1]:
An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for vandetanib

Vandetanib has been investigated in 6 clinical trials, of which 4 are open and 2 are closed. Of the trials investigating vandetanib, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), 3 are phase 2 (2 open), and 1 is phase 3 (1 open).

ER Positive, ERBB2 Amplification, and FH Loss are the most frequent biomarker inclusion criteria for vandetanib clinical trials.

Breast carcinoma, thyroid gland medullary carcinoma, and cancer are the most common diseases being investigated in vandetanib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Vandetanib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Vandetanib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating vandetanib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
azd6474, zd6474, Zactima, Caprelsa, caprelsa, zd 6474, vandetanib (substance), vandetanib, zd-6474, 443913-73-3, vandetanib (product), vandetanib
Drug Categories [2]:
Tyrosine kinase inhibitors
Drug Target(s) [2]:
ABL1, EGFR, FLT1, KDR, PTK6, RET, SRC, TEK
NCIT ID [1]:
C2737
SNOMED ID [1]:
C-781D8

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.